Junior tech and biotechs are still thriving. Pic Getty
ASX Quarterlies: Junior techs and biotechs still thriving despite difficult conditions
News
share
It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings lodgements.
Several small caps from Tech and Healthcare released their reports today, showing that they’re still thriving despite difficult conditions.
Tech sector
Dubber reported operating cash receipts for the quarter of $9.5m, up 42% QoQ.
Revenue was $6.6m, down 3% QoQ, up 10% YoY.
During the quarter, Dubber was accepted for the ‘IP Co-sell’ programme with Microsoft.
The company also extended its Service Provider footprint with commercial agreements with Ziggo (Vodafone Netherlands), 3 (UK) and NTS (USA).
In its sports betting business, Pointsbet reported an 18% increase in turnover (on pcp) to $1.156 billion for Q1.
Its net win rose 4% on pcp to $70.3m. During the quarter, the company continued to make traction in the US where it launched Kansas and Louisiana Online Sportsbooks and retail in Maryland.
The online sportsbook is now live in 12 US states, while iGaming is live in four states.
The SaaS company saw a 61% increase in Contractor MRR on Q1 FY22 to $232k, with a number of licences still to go live in the coming months.
For the quarter, Felix reported $2.9m Contractor ARR, an increase of 26% on pcp.
Two new contractors were signed in Q1, including a cornerstone customer in a commercial construction vertical.
In addition, two expansion deals signed in Q1 with the majority of existing customers licensing two modules, highlighting the significant expansion revenue opportunity.
Tech share prices today:
Biotech sector
GTG reported revenue from customers of $1.93 million for the quarter, up 375% from the pcp.
This highlights commercial progress as revenues are being generated from GTG’s three key brands: geneType, EasyDNA, and AffinityDNA.
Aora says its first half product revenue grew 44% on H1 FY22, and 20% on H2 FY22.
Total revenue for H1 FY23 (unaudited), inclusive of project fees, was NZ$29.3 million.
Aora has provided guidance for FY23 of NZ$62-64 million (including NZ$2 million of project and licence fees).
FY23 guidance for product gross margin has been upgraded to 84% on revised constant currency basis.
The sleep-related breathing disorders treatment company reported Q1 FY23 revenue of $18.5 million, up +19% on pcp.
SomnoMed says the strong performance reflects the impact of the sales and marketing initiatives in all regions, and the trend of growing patient and medical clinician adoption of Continuous Open Airway Therapy for the treatment of OSA (Obstructive sleep apnea).
Biotech share prices today:
Read MoreMarkets
